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Abstract 
Background 
Although chemotherapy for prostate cancer (PCa) can improve patient survival, some 
tumours are chemo-resistant. Tumour molecular profiles may help identify the mechanisms 
of drug action and identify potential prognostic biomarkers. We performed in vivo 
transcriptome profiling of pre- and post-treatment prostatic biopsies from patients with 
advanced hormone-naive prostate cancer treated with docetaxel chemotherapy and androgen 
deprivation therapy (ADT) with an aim to identify the mechanisms of drug action and 
identify prognostic biomarkers. 
Methods 
RNA sequencing (RNA-Seq) was performed on biopsies from four patients before and ~22 
weeks after docetaxel and ADT initiation. Gene fusion products and differentially-regulated 
genes between treatment pairs were identified using TopHat and pathway enrichment 
analyses undertaken. Publically available datasets were interrogated to perform survival 
analyses on the gene signatures identified using cBioportal. 
Results 
A number of genomic rearrangements were identified including the TMPRSS2/ERG fusion 
and 3 novel gene fusions involving the ETS family of transcription factors in patients, both 
pre and post chemotherapy. In total, gene expression analyses showed differential expression 
of at least 2 fold in 575 genes in post-chemotherapy biopsies. Of these, pathway analyses 
identified a panel of 7 genes (ADAM7, FAM72B, BUB1B, CCNB1, CCNB2, TTK, CDK1), 
including a cell cycle-related geneset, that were differentially-regulated following treatment 
with docetaxel and ADT. Using cBioportal to interrogate the MSKCC-Prostate Oncogenome 
Project dataset we observed a statistically-significant reduction in disease-free survival of 
patients with tumours exhibiting alterations in gene expression of the above panel of 7 genes 
(p = 0.015). 
Conclusions 
Here we report on the first “real-time” in vivo RNA-Seq-based transcriptome analysis of 
clinical PCa from pre- and post-treatment TRUSS-guided biopsies of patients treated with 
docetaxel chemotherapy plus ADT. We identify a chemotherapy-driven PCa transcriptome 
profile which includes the down-regulation of important positive regulators of cell cycle 
progression. A 7 gene signature biomarker panel has also been identified in high-risk prostate 
cancer patients to be of prognostic value. Future prospective study is warranted to evaluate 
the clinical value of this panel. 
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Background 
The mainstay of treatment for “incurable” locally-advanced/metastatic prostate cancer (PCa) 
is androgen deprivation therapy (ADT) [1], however after ~2-3 years the disease becomes 
castration-resistant (CRPCa). Historically, patients with CRPCa exhibited a median survival 
of less than ~18 months, although this has improved since the advent of novel chemo- and 
endocrine therapies [2]. The anti-mitotic agent docetaxel was the first chemotherapeutic agent 
to demonstrate a significant survival advantage for patients with CRPCa [3,4]. Docetaxel 
stabilizes microtubules, thereby interrupting microtubule dynamics (including the mitotic 
spindle) causing mitotic arrest and accumulation of cells in G2/M (due to failure chromosome 
segregation and cytokinesis) and apoptosis [5,6]. 
Early trials demonstrated an overall median ~2-3 month survival advantage for docetaxel-
based therapies over standard treatments for CRPCa [3,4], supporting its recommendation as 
first-line standard of care for CRPCa [1]. However, only ~50% of patients with CRPCa will 
respond to docetaxel, and the modest survival advantage is at the cost of significant toxicity 
[3,4]. Recently, docetaxel plus ADT have been found to confer no statistically-significant 
survival advantage over ADT alone for non-CRPCa (i.e. hormone-naïve disease), despite an 
improvement in clinical and biochemical progression-free survival [7]. 
An understanding of the biology of de novo and acquired chemo-resistance to docetaxel (and 
other agents) in PCa with in-parallel biomarker discovery will help to identify patients who 
will not benefit from treatment prior to exposure, thereby avoiding unnecessary toxicity and 
guiding more effective therapeutic options. Aided by technological advances such as next 
generation sequencing which facilitate whole genome and transcriptome analyses, molecular 
profiling of pre- and post-treatment tumour samples may help to identify the mechanisms of 
drug action and link specific gene amplifications and mutations or expression changes to 
clinical chemo-sensitivity or -resistance patterns [8]. 
Previously-published transcriptome-wide analyses of docetaxel action and chemo-resistance 
in PCa have utilised microarrays for assessment of pre- and post-extirpative surgical 
specimens [9,10] and in vitro cell lines [3,11-13]. However, these studies are limited by the 
inherent bias and quantitative nature of microarray data [14]. We performed in vivo 
transcriptome profiling by next generation RNA sequencing (RNA-Seq) of pre- and post-
treatment transrectal ultrasound (TRUSS)-guided prostatic biopsies from patients with newly-
diagnosed locally-advanced/metastatic non-CRPCa treated with docetaxel chemotherapy plus 
ADT. 
Methods 
Patient samples 
Patient samples for gene expression analysis (RNA-Seq) were collected as part of the 
GenTax (Tumour profiling in an open-labelled, two-arm study investigating the tolerability 
and efficacy of Taxotere in patients with hormone-naïve high-risk prostate cancer) study by 
Newcastle upon Tyne Hospitals National Health Service (NHS) Foundation Trust [15]. All 
patients with a clinical suspicion of advanced PCa were subjected to TRUSS-guided prostatic 
biopsy (BK Medical, 8818) for histopathological assessment by Gleason Sum score [16] of 
Haematoxylin and Eosin (H&E)-stained tissue. Radiological staging investigations were 
performed according to national guidelines [17]. Patient eligibility criteria were cT3/T4 [18] 
PCa, Prostate Specific Antigen (PSA) ≥50 ng/ml or Gleason Sum score ≥8, or metastatic 
disease to be commenced on ADT. Further eligibility for study inclusion were Karnofsky 
Performance status (KPS) Score [19] ≥ 70%; a life expectancy of ≥ 3 months; and adequate 
haematological, hepatic, and renal function. All patients received ADT, which consisted of 
the goserelin 3.6 mg on a q28-day schedule with anti-androgen “flare” protection and 6 
cycles of docetaxel (Taxotere®) 75 mg/m2 on a q21-day schedule [15]. Further material for 
RNA-Seq was taken by TRUSS-guided biopsy prior to commencement of chemotherapy and 
again at ~22 weeks following initiation of treatment. Biopsies were specifically taken from 
tumour-rich areas of the prostate, where typically over 60% of the initial diagnostic cores 
taken were occupied by tumour. All patient material was anonymized and stored at −80°C. 
Serum PSA was measured ~3-weekly until ~22 weeks and then 3-monthly, and repeat 
radiological staging undertaken at ~6 months after diagnosis for patients with N+ and/or M+ 
disease to assess the radiological response. PSA progression was defined as two consecutive 
rises in PSA above nadir at least 2 weeks apart, although whether patients subsequently 
fulfilled the European Association of Urology (EAU) criteria for castration resistant PCa 
disease [1] is not known. Written informed consent to participate was obtained from all 
subjects. Ethical approval was granted from the local research and ethics committee 
(Northumberland, Tyne and Wear NHS Strategic Health Authority Local Research Ethics 
Committee Ref: 2003/11). 
RNA extraction and RNA-Seq 
Patient samples for RNA-Seq were analysed as previously described [20]. Total RNA was 
extracted from pre- and post-treatment samples using the RNeasy Mini Kit (QIAgen, 74104) 
according to manufacturer’s instructions. The NanoDrop 2000 spectrophotometer (Thermo 
Scientific) and 2100 Bioanalyzer (Agilent) were used to assess RNA quantity and quality, 
with calculation of RNA integrity number (RIN) [21]. Samples were included for RNA-Seq if 
RIN > 6 and total RNA > 500 ng. Illumina RNA-Seq was performed according to 
manufacturer’s instructions, with cDNA sample library normalization using the Illumina 
DSN (Duplex-specific Nuclease) protocol prior to cluster generation and library sequencing 
on the HiSeq™ 2000 (Illumina) with a paired-end sequencing strategy. The read length was 
set at 90 nt with an expected library size of 200 bp. 
Bioinformatics 
The FastQC package (http://www.bioinformatics.babraham.ac.uk/projects/fastqc) was used to 
assess the quality of raw reads, which were then mapped to human genome assembly hg19 
using TopHat version 1.4.1 [22] with a junctions library derived from Ensembl version 68. 
Quality control was performed on all samples by examining the following parameters: (a) the 
percent of reads uniquely mapping to the genome; (b) the percent of reads mapping to known 
protein coding sequence; (c) the number of exon junctions identified; (d) the percent of 
spliced reads; and (e) the number of genes with 90% base coverage (Additional file 1: Table 
S1). TopHat-Fusion version 0.1.0 [23] was used to identify gene fusions. HTSeq version 
0.5.3 (http://www.huber.embl.de/users/anders/HTSeq) was used to identify differentially-
expressed genes by counting the number of reads mapping to each gene from Ensembl 
version 68. The TMM method was used to normalise read counts and differential expression 
tested for using a paired generalized linear model design with the Bioconductor version 2.11 
edgeR package [24]. The Circos plot was generated using RCircos version 1.1.2 [25]. 
Correlations were identified using Pearson’s product moment correlation coefficient (p < 
0.05). Enriched KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways [26] were 
identified by downloading gene pathways associations and testing each pathway for 
enrichment in significantly up- and down-regulated genes (FDR < 0.05) with a transcript 
length-corrected Wallenius approximation as implemented by the GOSeq package for 
Bioconductor 3.0 [27]. Pathways were deemed to be enriched if the enrichment over 
background was at least 2-fold and the FDR < 0.05. Gene lists were uploaded to cBioPortal 
(http://www.cbioportal.org) [28,29] to study gene expression changes in all prostate tumours 
with mRNA expression data (n = 150) from the Memorial Sloan Kettering Cancer Center 
(MSKCC) Prostate Oncogenome Project dataset [30] using a mRNA Z-score threshold of ± 
1.6 as compared with normal prostate samples. Genes altered in a significant number of 
tumours (>25%) were considered for associations with disease-free survival though the 
cBioPortal software using the Kaplan–Meier method with log rank testing with p < 0.05 
taken to indicated statistical significance. Raw sequencing data have been deposited at Gene 
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE51005 
and all details are MIAME compliant. 
Results 
The transcriptomic landscape of docetaxel chemotherapy plus ADT in PCa 
Next generation RNA sequencing (RNA-Seq) was performed on 12 paired pre- and post-
docetaxel plus ADT samples from 6 patients with locally-advanced/metastatic PCa (Table 1). 
The post-treatment samples from Patients 2 and 3 performed markedly worse on multiple 
quality control measures, and so all samples from both patients were excluded from further 
quantitative expression analysis (Additional file 1: Table S1). The remaining 8 samples 
matched our previously-published dataset on the ADT-only control arm of the GenTax study 
[20] on two key quality control measures: At least 50 million 90 bp paired-end reads were 
obtained per sample with at least 40% coverage of transcripts sequenced (Additional file 1: 
Table S1). 
Table 1 Patient demographics of samples for RNA-Seq following docetaxel chemotherapy plus ADT 
Patient KPS GSS T N M iPSA (ng/ml) nPSA (ng/ml) (%iPSA) PFS (days) 
1 90 9 4 1 1 8.76 0.09 (1.0) 317 
2* 90 7$ 3b 1 0 8.44 1.3 (15.4) 105 
3* 90 8 3b 0 0 25.8 0.19 (0.7) 834 
4 90 7 3b 1 1 80.8 0.08 (0.1) 588 
5 90 9 3b 0 0 2.85 0.08 (2.8) N/P 
6 90 7 3b 1 1 636 0.1 (0.0) N/P 
All patients exhibited a response to docetaxel plus ADT prior to second TRUSS-guided biopsy as determined by a fall in levels of serum PSA. 
The mean time to second TRUSS-guided biopsy was 156 ± 37 days. *Samples removed from RNA-seq analysis. $Tertiary Gleason grade 5. 
(KPS = Karnofsky Performance Status; GSS = Gleason Sum Score; iPSA = initial PSA value at diagnosis; nPSA = nadir PSA value prior to 
second TRUSS-guided biopsy; PFS = biochemical progression-free survival; N/P = not yet progressed). 
Genomic rearrangements involving ETS-family transcription factors are implicated in PCa 
with the most common gene fusion product TMPRSS2/ERG reported in >50% cases [31]. We 
searched for expression of transcripts derived from such gene fusions in our datasets. We 
observed the intra-chromosomal TMPRSS2/ERG gene fusion product in only the pre-
treatment sample from 1 patient (Patient 3), which was actually excluded from the 
quantitative expression analysis (Additional file 2: Table S2). However, we observed 3 
further novel intra-chromosomal gene fusions: two products were derived from a fusion 
between DOPEY2 and ERG genes within chromosome 21 (Fusion event 7), and 2 different 
gene fusions were observed within chromosome 22 (Fusion events 3 and 4) (Figure 1A). A 
further five novel fusion transcripts were identified (Figure 1A and Additional file 2: Table 
S2). In three patients, identical inter- and intra-chromosomal gene fusions (CCNY/LRCC49, 
PVT1/CPNE4, and DOPEY2/ERG) were identified in both pre- and post-treatment samples. 
Figure 1 Differential expression of androgen-regulated genes in response to docetaxel 
chemotherapy plus ADT. (A) Circos plot [25] of the transcriptomic landscape of docetaxel 
chemotherapy plus ADT in PCa. The outer ring shows chromosome ideograms with labelled 
chromosome identities. The scatter plot shows up- (Red) and down- (Blue) regulated genes. 
Gene fusions are shown as coloured arcs linking two genomic loci. (B) Log-log plot 
demonstrating correlation between KLK3 (encodes PSA) mRNA expression levels (X-axis) 
normalized by trimmed means of M-value (TMM) in normalized counts per million (ncpm) 
and serum PSA levels (ng/ml) (Y-axis) (r2 = 0.927; p = 0.037). (C) Expression of known 
androgen-regulated genes (Log2 fold change ≥ 2; FDR < 0.05) following docetaxel plus 
ADT. 
Across the genome, we observed a total of 298 genes up-regulated and 277 genes similarly 
down-regulated at least 2-fold (False Discovery Rate [FDR] <0.05) in response to docetaxel 
plus ADT (Figure 1A, Table 2 and Additional file 3: Table S3). The levels of expression of 
KLK3, which encodes PSA (Prostate Specific Antigen), detected by RNA-Seq of the 
docetaxel plus ADT arm correlated as expected with serum PSA levels (r2 = 0.927; p = 0.037) 
(Figure 1B). A number of other known androgen-regulated genes (including those encoding 
kallikreins) were also consistently down-regulated in the docetaxel plus ADT arm (Figure 
1C) suggesting that ADT in combination with docetaxel had the expected action on 
androgen-regulated gene expression. 
Table 2 Differentially-expressed genes following docetaxel chemotherapy plus ADT 
versus ADT alone 
Gene set Tax ADT 
Up Down Up Down 
Protein Coding 298 277 774 755 
Non-Coding 7 15 35 116 
Numbers of protein coding and non-coding genes differentially expressed at least 2-fold after 
ADT with FDR < 0.05. (ADT = androgen deprivation therapy; Tax = docetaxel + ADT). 
Based on the full gene list (Log2 fold change ≥2/≤ − 2; FDR < 0.05) (Table 2 and Additional 
file 3: Table S3), we ranked genes according to the magnitude of their fold changes, 
regardless of whether they were up- or down-regulated. The 10 top-ranking genes 
differentially-regulated by docetaxel plus ADT were arbitrarily selected (range of fold 
changes −9.96 to 9.86) for further downstream knowledge-based validation. From these 10 
genes, we selected genes that exhibited expression changes consistent in direction in at least 3 
out of 4 patients. We identified 6 differentially-expressed genes (Figure 2A) including 
ORM1, which had the highest average level of differential expression of all transcripts in our 
dataset (Log2 fold change = −9.96; FDR < 0.05). This gene encodes an acute phase plasma 
protein that has been identified as a putative biomarker of chemo-resistance to docetaxel and 
doxorubicin in breast cancer [13]. 
Figure 2 Differential expression of genes affected by docetaxel chemotherapy plus ADT. 
(A) Log2 fold change of 6 of the 10 top-ranking differentially-expressed genes (Log2 fold 
change ≥ 2/≤ − 2; FDR < 0.05) consistent in the direction of expression changes in at least 3 
out of 4 individual patients. (B) Matrix heatmap generated using cBioPortal [28,29] showing 
alterations in expression of 6 of the top 10 differentially-regulated genes (exhibiting 
consistent expression changes in at least 3 out of 4 patients in the present study) in the 
MSKCC Prostate Oncogenome Project dataset [30]. (C) Kaplan Meier plot showing the 
survival curves of patients in the MSKCC Prostate Oncogenome Project dataset with and 
without alterations in expression of FAM72B and ADAM7 (p = 0.001). 
Using cBioPortal [28,29], we interrogated the MSKCC Prostate Oncogenome Project dataset 
(n = 150) [30] for changes in expression of the above 6 genes in treatment-naive prostate 
tumours as compared with normal controls. We observed alterations in expression of all 6 
genes, with FAM72B and ADAM7 exhibiting significant alterations (Figure 2B). Survival 
analysis identified a statistically-significant reduction in disease-free survival of patients with 
tumours exhibiting alterations in expression of this geneset (p = 0.023) (Additional file 4: 
Figure S1A) which was lost when FAM72B and ADAM7 were removed from the geneset (p > 
0.05) (data not shown). Using only FAM72B and ADAM7, survival analysis demonstrated a 
statistically-significant disease-free survival advantage in patients with no alterations in gene 
expression (p = 0.001) (Figure 2C). Taken together, these data suggest that alterations in 
expression of FAM72B and ADAM7 are associated with early treatment relapse and hence 
may be biomarkers with prognostic value in treatment-naïve PCa. 
Pathway analyses of gene expression changes in response to docetaxel 
chemotherapy and ADT 
To identify biological pathways perturbed by combined docetaxel chemotherapy with ADT, 
we performed an enrichment analysis on our lists of up- and down-regulated genes (FDR < 
0.05) using 3 different pathways analysis tools: the KEGG (Kyoto Encyclopedia of Genes 
and Genomes) database [26]; IPA “Core Analysis” function; and Metacore (Figure 3 and 
Additional file 5: Figure S2, Additional file 6: Table S4 and Additional file 7: Table S5). The 
KEGG terms “Cell Cycle” (n = 11/124; enrichment = 5.89-fold; FDR = 0.0014) and “Steroid 
Biosynthesis” (n = 5/19; enrichment = 17.63-fold; FDR = 0.0014) were enriched greater than 
2-fold in the down-regulated gene list (Additional file 6: Table S4), while no pathways were 
significantly enriched in the up-regulated gene list. Genes within the KEGG term “Cell 
Cycle” included the key positive cell cycle regulators CCNB1, CCNB2, CDK1 and CDC25A 
(Figure 3A and Additional file 8: Table S6), the expression of which was down-regulated 
following docetaxel plus ADT. The Ingenuity Pathway Analysis “Core Analysis” function 
also identified the “Cell Cycle” as the highest-ranking network containing clusters of 
docetaxel and ADT-regulated genes (Additional file 5: Figure S2A and Additional file 7: 
Table S5). Metacore analysis of docetaxel and ADT-regulated genes identified Cell cycle 
“The metaphase checkpoint” as the 2nd top enriched pathway after Cytoskeleton remodelling 
“Keratin filaments”, which is consistent with the known actions of docetaxel (Additional file 
5: Figure S2B). 
Figure 3 Pathway analyses of gene expression changes in response to docetaxel 
chemotherapy with ADT. (A) Log2 fold change of genes enriched (enrichment > 2-fold; 
FDR < 0.05) within the KEGG (Kyoto Encyclopedia of Genes and Genomes) [26] term “Cell 
Cycle” following docetaxel plus ADT treatment. (B) Matrix heatmap generated using 
cBioPortal [28,29] showing alterations in expression of 5 genes from within the KEGG term 
“Cell Cycle” (BUB1B, CCNB1, CCNB2, TTK, and CDK1) in the MSKCC Prostate 
Oncogenome Project dataset [30]. (C) Kaplan Meier plot showing the survival curves of 
patients in the MSKCC Prostate Oncogenome Project dataset with and without alterations in 
expression of the 5 cell cycle-related genes (p = 0.024). (D) Kaplan Meier plot showing the 
survival curves of patients in the MSKCC Prostate Oncogenome Project dataset with and 
without alterations in expression of the genes in the candidate biomarker panel (ADAM7, 
FAM72B, BUB1B, CCNB1, CCNB2, TTK and CDK1) (p = 0.015). 
The observed enrichment for cell cycle-related genes, including down-regulation of 
expression of positive regulators of cell cycle progression, is in keeping with the known 
actions of docetaxel in vitro on the induction of G2/M arrest [5]. In the light of evidence 
suggesting that androgen withdrawal may diminish docetaxel-induced apoptosis in vitro [32], 
we wished to ensure that our in vivo observations were consistent with the mechanism of 
action of docetaxel in vitro in the absence of androgens. We used the LNCaP PCa cell line 
grown in steroid-depleted medium as a model for non-CRPCa treated with ADT. 
Reassuringly, we observed statistically-significant induction of G2/M arrest (p < 0.05) 
following treatment with docetaxel (at 10nM, 100nM or 1 µM doses) (Additional file 5: 
Figure S2C). 
Finally, we used cBioPortal [28,29] to interrogate the MSKCC Prostate Oncogenome Project 
dataset [30] for changes in expression of the genes enriched within the KEGG term “Cell 
Cycle” in clinical PCa and observed alterations in expression of all genes in a large (78%) 
proportion of cases (Additional file 5: Figure S2D), suggesting that expression of these 
transcripts is associated with prostate tumourigenesis. Survival analyses did not identify any 
statistically-significant associations between disease-free survival time in patients with 
tumours exhibiting alterations in expression of these genes as compared with patients with 
tumours exhibiting no alterations in expression (p > 0.05) (data not shown). However, when 
genes exhibiting alterations in high (>25%) proportion of tumours only were included in this 
geneset (Figure 3B), we observed statistically-significant reduction in disease-free survival of 
patients with tumours exhibiting alterations in expression of this geneset (p = 0.024) (Figure 
3C). Using a combined geneset of these 5 remaining cell cycle-related genes (BUB1B, 
CCNB1, CCNB2, TTK and CDK1) as well as ADAM7 and FAM72B, we also observed a 
statistically-significant reduction in disease-free survival of patients with tumours exhibiting 
alterations in gene expression (p = 0.015) (Figure 3D). Our observations suggest that these 7 
genes in combination could form a panel of biomarkers associated with early relapse from 
treatment in clinical PCa. 
Discussion 
To the best of our knowledge, our study is the first “real time” in vivo RNA-Seq-based 
transcriptome analysis of clinical PCa from pre- and post-treatment TRUSS-guided biopsies 
of patients treated with docetaxel chemotherapy plus ADT. The limitations of our study 
include a targeted TRUSS-guided needle-core biopsy strategy that may result in 
heterogeneous tissue sampling with variable cellularity and small sample numbers due to the 
high quality RNA required for RNA-Seq (RIN > 6 and total RNA > 500 ng). Despite using 
fresh-frozen tissue samples, the high sample attrition rate (33%) from analyses prevented 
more meaningful clinical outcomes, such as treatment response, to be extrapolated from our 
results. Nonetheless, we clearly demonstrate the feasibility of this in vivo approach to obtain 
informative transcriptomic data from small tissue samples pre- and post-treatment with 
cytotoxic chemotherapy. As tissue sample processing and RNA-Seq methodologies are 
further refined, it may become possible to obtain reliable sequencing information from low 
input and/or degraded clinical samples [33]. 
The transcriptomic landscape of PCa includes gene fusion products as a result genomic 
rearrangements [31]. We observed transcripts derived from the commonly-reported 
TMPRSS2/ERG gene fusion as well as other inter- and intra-chromosomal gene fusions. 
Incorporating different samples from our previously-published RNA-Seq dataset from the 
same study cohort [20], we observed transcripts arising from the TMPRSS2/ERG fusion in 
28% of all pre-treatment samples. These observations are comparable to the frequency of 
TMPRSS2/ERG fusions reported in Caucasian populations [34] as well as in an Asian cohort 
analysed by RNA-Seq [35]. 
Our analysis of docetaxel plus ADT-driven gene expression changes identified two 
differentially-regulated genes ADAM7 and FAM72B, which were also mis-regulated in a 
large proportion of prostate tumours from a large cohort of different patients and associated 
with shorter disease-free survival after treatment. Additionally, we identified enrichment for 
cell cycle-related genes, including the down-regulation of expression of some positive 
regulators of cell cycle progression ~4 weeks after the final cycle of docetaxel chemotherapy. 
Our observations were somewhat reassuring, as docetaxel in combination with ADT in vivo 
appears to exhibit an expected mechanism of action on cell cycle progression. Furthermore, 
we demonstrated that androgen withdrawal did not affect the dose-dependent induction of 
G2/M by docetaxel in vitro. Taken together, our data suggest a persistent anti-tumourigenic 
effect of docetaxel in combination with ADT in vivo. However the longevity of this response 
may be limited, as a previous study of docetaxel-treated tumours identified persistent PCa 
several months after treatment [36]. 
Finally, we identify a biomarker panel of 7 genes (ADAM7, FAM72B, BUB1B, CCNB1, 
CCNB2, TTK and CDK1), which included a cell cycle-related geneset, that was not only mis-
regulated in a significant proportion of treatment-naïve PCa specimens, but also associated 
with early relapse after treatment. Recently, there has been considerable interest in the use of 
cell cycle-related genes as biomarkers of disease progression to aid treatment decisions. The 
cell cycle progression (CCP) test (Prolaris®, Myriad Genetics) is a prognostic assay based on 
a 46-gene expression signature that includes cell cycle-related genes, which, in combination 
with standard clinicopathological parameters, accurately stratifies patients with primary PCa 
to the risk of PCa-specific disease progression and disease-specific mortality [37]. Based on 
our preliminary findings, it is also possible that the CCP test may be useful to determine the 
risk of disease relapse after cytotoxic chemotherapy for advanced PCa. 
Our study exemplifies the feasibility of in vivo RNA-Seq-based tumour molecular profiling 
from pre- and post-treatment biopsies from chemotherapy-treated patients [8] for advanced 
PCa to highlight the mechanisms of drug action and identify putative biomarkers of chemo-
sensitivity or –resistance to (such as ORM1) and/or prognosis (such as ADAM7 and FAM72B, 
and the cell cycle-related genes). Our preliminary findings suggest that a 7 gene signature 
biomarker panel, which includes cell-cycle related genes, may have prognostic value in 
treatment-naïve clinical PCa and warrants further investigation. Further similar larger-scale 
studies with high-quality outcomes data will be required to allow development of a complete 
oncogenomic personalised approach to patient care for advanced/metastatic PCa, with 
prognostication and treatment scheduling based on oncogenomic profiles to maximise 
chemotherapy efficacy [38]. 
Conclusions 
Here we report on the first “real-time” in vivo RNA-Seq-based transcriptome analysis of 
clinical PCa from pre- and post-treatment TRUSS-guided biopsies of patients treated with 
docetaxel chemotherapy plus ADT. We have identified a chemotherapy-driven PCa 
transcriptome profile which includes the down-regulation of important positive regulators of 
cell cycle progression. A 7-gene signature biomarker panel has been identified in high-risk 
prostate cancer patients to be of prognostic value. Future prospective study is warranted to 
evaluate the clinical value of this panel. 
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